HHC
HAE icon

Hutchin Hill Capital’s Haemonetics HAE Stock Holding History

Hutchin Hill Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$465K Sell
8,000
-19,000
-70% -$1M 0.13% 179
2017
Q3 		$1.21M Buy
+27,000
New +$1.12M 0.05% 301
2017
Q2 		– Sell
-94,000
Closed -$3.81M – 918
2017
Q1 		$3.81M Buy
94,000
+49,500
+111% +$1.93M 0.1% 213
2016
Q4 		$1.79M Buy
+44,500
New +$1.68M 0.06% 332
2013
Q4 		– Sell
-16,000
Closed -$638K – 567
2013
Q3 		$638K Buy
+16,000
New +$671K 0.06% 272

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hutchin Hill Capital's HAE Position: Q4 2017 in Review

Hutchin Hill Capital reduced its Haemonetics (HAE) stake by 70% in Q4 2017, selling an estimated $1M and leaving 8,000 shares worth $465K. The position accounts for 0.13% of the portfolio, ranked #179.

Hutchin Hill Capital first reported a position in HAE in Q3 2013 and has held it in 5 quarters since. The position peaked at $3.81M in Q1 2017. 246 funds tracked by Wall St. Rank hold HAE as of Q4 2017.

  • Hutchin Hill Capital held 8,000 shares of Haemonetics worth $465K as of Q4 2017.
  • Hutchin Hill Capital sold 19,000 Haemonetics shares in Q4 2017, an estimated $1M.
  • Haemonetics made up 0.13% of Hutchin Hill Capital's portfolio in Q4 2017, its #179 holding.
  • Hutchin Hill Capital first reported a position in Haemonetics in Q3 2013 and has held it in 5 quarters since.
  • Hutchin Hill Capital's Haemonetics position peaked at $3.81M in Q1 2017.
  • 246 funds tracked by Wall St. Rank held Haemonetics as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.